Pharmafile Logo
Pharmafocus logo
Advanced Search

acute myeloid leukaemia

Showing 15 posts of 20 posts found.

Gilteritinib becomes first NICE-approved oral therapy for relapsed or refractory acute myeloid leukaemia

July 16, 2020
Sales and Marketing Atellas, NICE, UK, acute myeloid leukaemia, gilteritinib

NICE has revealed its recommendation of Astellas’ gilteritinib for routine use as a monotherapy on the NHS in England and …

News

NICE declines to recommend Astellas’ Xospata in rlapsed/refractory FLT3+ acute myeloid leukaemia

January 23, 2020
Sales and Marketing Astellas, NHS, NICE, UK, Xospata, acute myeloid leukaemia

The latest in a series of rejections over the past week, NICE has revealed that it has knocked back the …

News

Bristol-Myers Squibb drug boasts strong overall survival in acute myeloid leukaemia

December 11, 2019
Research and Development ASH 19, Bristol-Myers Squibb, acute myeloid leukaemia, pharma

Bristol-Myers Squibb took the opportunity at the 2019 American Society of Hematology (ASH) Annual Meeting to reveal new efficacy data …

News

Living with acute myeloid leukaemia

September 23, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute myeloid leukaemia, feature, patient experience, pharma

Steve Rothberg was blindsided by an AML diagnosis that progressed rapidly with little warning. Ten years later, he discusses his …

Feature
amgen_flag

Amgen unveils double whammy of data for its investigational cancer immunotherapies at ASH 2018

December 5, 2018
Research and Development ASH 2018, Amgen, Cancer, acute myeloid leukaemia, myeloma, pharma

Amgen has presented the first clinical data at the American Society of Hematology (ASH) Annual Meeting 2018 for two investigational …

News
jazz_pharma

Jazz Pharma’s Vyxeos secures NICE recommendation in acute myeloid leukaemia

November 8, 2018
Sales and Marketing Cancer, NHS, NICE, UK, Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, pharma

Jazz Pharmaceuticals has revealed that NICE has chosen to recommend that its 44mg/100mg powder formulation of Vyxeos for concentrate for …

News

NICE recommends Pfizer’s Mylotarg combo in CD33-positive acute myeloid leukaemia

October 8, 2018
Sales and Marketing Mylotarg, NICE, Pfizer, acute myeloid leukaemia, leukaemia, pharma

NICE has revealed its recommendation for Pfizer’s Mylotarg (gemtuzumab ozogamicin) to be used on the NHS in the treatment of …

News
jazz_pharma

Jazz Pharma’s acute myeloid leukaemia drug scores EU approval

August 29, 2018
Research and Development, Sales and Marketing Vyxeos, acute myeloid leukaemia, jazz pharmaceuticals, leukaemia, pharma

Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment …

News
novartis_window

Novartis nets first acute myeloid leukaemia approval in Canada, but NICE says no

December 6, 2017
Research and Development, Sales and Marketing Canada, NICE, Novartis, Rydapt, UK, acute myeloid leukaemia, leukaemia, pharma

Novartis is celebrating the news that its drug Rydapt (midostaurin) has been awarded marketing approval in Canada for the treatment …

News
novartis_side_building

Novartis scores EU approval in acute myeloid leukaemia and advanced systemic mastocytosis

September 20, 2017
Research and Development, Sales and Marketing EU, Europe, Novartis, acute myeloid leukaemia, advanced systemic mastocytosis, pharma, pharmaceutical

Novartis has announced that its targeted therapy Rydapt (midostaurin) has received EU approval in the two rare cancer indications: newly …

News
celgene_1_02

FDA approves Celgene and Agios’ acute myeloid leukaemia drug

August 2, 2017
Research and Development, Sales and Marketing Celgene, FDA, Idhifa, acute myeloid leukaemia, agios, biotech, drugs, life sciences, medicines, pharma, pharmaceuticals

The FDA has given its approval for the commercialisation of Celgene and Agios Pharmaceutical’s Idhifa for the treatment of relapsed …

News
acute_leukemia-all

New drug combination gives hope for acute myeloid leukaemia treatment

March 8, 2017
Research and Development acute myeloid leukaemia

A new trial in the US hopes to marry a new pair of drugs as a combination treatment for acute …

News

Experimental Novartis leukaemia and mastocytosis drug gets FDA Priority Review

November 14, 2016
Research and Development, Sales and Marketing FDA, Novartis, acute myeloid leukaemia

The US FDA has granted Priority Review status to Novartis’ experimental drug PKC412 (midostaurin) as a treatment for advanced systemic …

News
celgene_1_02

Celgene and Agios to file FDA application for “first-in-class” cancer drug

September 8, 2016
Research and Development, Sales and Marketing Celgene, FDA, NDA, acute myeloid leukaemia, agios

According to an SEC 8-K filing by Agios, the company and its partner Celgene intend to file a new drug …

News
clinical_trial_3

Celator receives FDA breakthrough therapy designation for leukaemia drug

May 20, 2016
Medical Communications, Research and Development FDA, Vyxeos, acute myeloid leukaemia, breakthrough therapy, celator

A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals (NASDAQ: CPXX) has been granted breakthrough …

News

Latest content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

September 21, 2023

EC approves Menarini Group’s Orserdu for breast cancer treatment

September 21, 2023

Pharmanovia acquires CNS portfolio from Sanofi

September 20, 2023

Exscientia enters AI drug discovery collaboration with Merck KGaA

September 20, 2023

EC approves Pfizer’s Litfulo for adolescents and adults with alopecia

September 19, 2023